Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 7/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 4/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13732818 | 0.91 | NR1H2 (0.36) | PDE4DPDE4APDE4BPDE4CNR1H2 | |
| SCHEMBL13733056 | 0.85 | NR1H2 (0.38) | NR1H2NAMPTNPC1XIAPBIRC2 | |
| SCHEMBL13736069 | 0.85 | XIAP (0.34) | PDE4DPDE4APDE4BPDE4CNR1H2 | |
| SCHEMBL13733437 | 0.85 | XIAP (0.36) | PTGS1PTGS2ALOX5MAPTMEN1 | |
| SCHEMBL19474781 | 0.81 | XIAP (0.36) | PTGS1PTGS2ALOX5MAPTRAB9A | |
| SCHEMBL13733738 | 0.80 | XIAP (0.45) | PTGS1PTGS2ALOX5NR1H2XIAP | |
| SCHEMBL25738272 | 0.80 | NR1H2 (0.39) | NR1H2MAPTMEN1KMT2AXIAP | |
| SCHEMBL31725835 | 0.80 | NR1H2 (0.39) | NR1H2XIAPBIRC2KDM1A | |
| Hydrochloric Acid SCHEMBL15649416 | 0.80 | XIAP (0.36) | PTGS1PTGS2ALOX5XIAPBIRC2 | |
| SCHEMBL13733393 | 0.80 | UCHL1 (0.36) | NR1H2HPGDNAMPTXIAPBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| EP-2699562-B1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| EP-2909196-B1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-2909198-B1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2020-10-14 | — | — | EP | disclosed |
| US-10781205-B2 | Conjugates comprising RIPK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-20190119271-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-25 | — | — | US | disclosed |
| US-9980973-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20170334907-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-20150291586-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-20150259359-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| EP-2909198-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | Astex Therapeutics Limited (GB) | 2015-08-26 | — | — | EP | disclosed |
| EP-2909196-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | Astex Therapeutics Ltd. (GB) | 2015-08-26 | — | — | EP | disclosed |
| US-9018214-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-28 | — | — | US | disclosed |
| US-20140179666-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| WO-2014060770-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060767-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2014-04-24 | — | — | WO | disclosed |
| EP-2699562-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | Astex Therapeutics Limited (GB) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143726-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781205-B2 | Conjugates comprising RIPK2 inhibitors | RIPK2, RIPK1, RIPK4 | PDE4D 4247/4885PDE4A 3851/4885PDE4B 3647/4885 |
| US-20190119271-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | RIPK2, RIPK1, RIPK4 | PDE4D 4247/4885PDE4A 3851/4885PDE4B 3647/4885 |
| US-20170334907-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | PDE4D 2336/4885PDE4A 2647/4885PDE4B 1991/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | PDE4D 2336/4885PDE4A 2647/4885PDE4B 1991/4885 |
| US-20150259359-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | PC, BAD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDE4D 1421/4885PDE4A 1780/4885PDE4B 1354/4885 |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | PDE4D 2336/4885PDE4A 2647/4885PDE4B 1991/4885 |
| US-20150291586-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | PDE4D 2336/4885PDE4A 2647/4885PDE4B 1991/4885 |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | PDE4D 2336/4885PDE4A 2647/4885PDE4B 1991/4885 |
| US-20140179666-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | PDE4D 2336/4885PDE4A 2647/4885PDE4B 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.